Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2015 - 2023)
Spyre Therapeutics (SYRE) reported Depreciation & Amortization (CF) of $360000.0 for Q2 2023, down 4.76% on a YoY basis from $378000.0 in Q2 2022, and down 6.25% quarter-over-quarter from $384000.0 in Q1 2023.
Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2015 - 2023) Analysis & Trends
Spyre Therapeutics has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $360000.0 in Q2 2023.
- For the quarter ending Q2 2023, Depreciation & Amortization (CF) fell 4.76% year-over-year to $360000.0; the trailing twelve-month figure through Mar 2024 stood at $360000.0 (down 76.74% YoY), and the FY2023 full-year result was $744000.0, down 52.52% from the prior year.
- Depreciation & Amortization (CF) for Q2 2023 stood at $360000.0, down from $384000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $412000.0 in Q3 2021, with the low at $100000.0 in Q1 2019.
- Historically, Depreciation & Amortization (CF) has averaged $294500.0 across 5 years, with a median of $364500.0 in 2020.
- Annual changes were most pronounced in 2020 — Depreciation & Amortization (CF) soared 248.11% — and 2022, when it slipped 6.33%.
- Spyre Therapeutics' Depreciation & Amortization (CF) stood at $106000.0 in 2019, then soared by 248.11% to $369000.0 in 2020, then gained by 11.38% to $411000.0 in 2021, then fell by 6.33% to $385000.0 in 2022, then fell by 6.49% to $360000.0 in 2023.
- The last three Depreciation & Amortization (CF) figures came in at $360000.0 (Q2 2023), $384000.0 (Q1 2023), and $385000.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 360,000.00 |
| Jun 30, 2023 | 360,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Dec 31, 2021 | 411,000.00 |
| Dec 31, 2021 | 411,000.00 |
| Sep 30, 2021 | 412,000.00 |
| Sep 30, 2021 | 412,000.00 |
| Jun 30, 2021 | 398,000.00 |
| Jun 30, 2021 | 398,000.00 |
| Mar 31, 2021 | 355,000.00 |
| Mar 31, 2021 | 355,000.00 |